2 weeks Ago By Defense World Staff
Rhumbline Advisers lessened its holdings in shares of Akoya Biosciences, Inc. ( NASDAQ:AKYA – Free Report ) by 15.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.
The fund owned 28,732 shares of the company’s stock after selling 5,125 shares during the quarter. Rhumbline Advisers owned approximately 0.06% of Akoya Biosciences worth $67,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its stake in shares of Akoya Biosciences by 16.2% during the 2nd quarter.
Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock worth $158,000 after acquiring an additional 9,429 shares during the period. CIBC Asset Management Inc raised its position in shares of Akoya Biosciences by 176.0% in the 4th quarter.
CIBC Asset Management Inc now owns 115,644 shares of the company’s stock valued at $564,000 after buying an additional 73,737 shares in the last quarter. Silvercrest Asset Management Group LLC acquired a new stake in shares of Akoya Biosciences in the 1st quarter valued at $2,724,000. Parkman Healthcare Partners LLC increased its stake in shares of Akoya Biosciences by 28.
4% in the 4th quarter. Parkman Healthcare Partners LLC now owns 674,787 shares of the company’s stock valued at $3,293,000 after purchasing an additional 149,164 shares during the last quarter. Finally, Vanguard Group Inc.
lifted its holdings in shares of Akoya Biosciences by 3.3% in the first quarter. Vanguard Group Inc.
now owns 1,454,288 shares of the company’s stock worth $6,821,000 after acquiring an additional 46,131 shares during the last quarter. Institutional investors own 79.42% of the company’s stock.
Akoya Biosciences Trading Down 4.9 % Shares of Akoya Biosciences stock opened at $2.72 on Tuesday.
The stock has a fifty day moving average price of $2.49 and a 200-day moving average price of $2.95.
The company has a debt-to-equity ratio of 3.43, a current ratio of 2.73 and a quick ratio of 1.
98. The firm has a market cap of $134.33 million, a PE ratio of -1.
85 and a beta of 1.35. Akoya Biosciences, Inc.
has a 1 year low of $1.88 and a 1 year high of $6.31.
Analyst Upgrades and Downgrades AKYA has been the topic of several research reports. Piper Sandler decreased their price target on shares of Akoya Biosciences from $6.00 to $4.
00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Morgan Stanley lowered shares of Akoya Biosciences from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $4.00 to $3.
00 in a research note on Tuesday, August 6th. BTIG Research downgraded shares of Akoya Biosciences from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. JPMorgan Chase & Co.
downgraded Akoya Biosciences from an “overweight” rating to a “neutral” rating in a report on Tuesday, August 6th. Finally, Craig Hallum decreased their price objective on Akoya Biosciences from $7.50 to $7.
00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $6.
56. View Our Latest Analysis on AKYA About Akoya Biosciences ( Free Report ) Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.
Read More Five stocks we like better than Akoya Biosciences Ride Out The Recession With These Dividend Kings TJX Stock: A Buying Opportunity Before the Holiday Rush The Basics of Support and Resistance Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge The Top 3 Healthcare Dividend Stocks to Buy and Hold Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth Want to see what other hedge funds are holding AKYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akoya Biosciences, Inc. ( NASDAQ:AKYA – Free Report ).
Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter ..
